Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

NCT ID: NCT04706936

Last Updated: 2023-02-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-01
• Study Completion Date: 2024-04-30

Brief Summary

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.

Conditions

Relapsed or Refractory Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Anti-BCMA CAR-T (CBG-002)

All subjects were intravenous administrated with CBG-002.

Group Type: EXPERIMENTAL

anti-BCMA CAR-T

Intervention Type: BIOLOGICAL

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.

Cyclophosphamid

Intervention Type: DRUG

300mg/m2/d

Fludarabine

Intervention Type: DRUG

30mg/m2/d

Interventions

anti-BCMA CAR-T

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.

Intervention Type: BIOLOGICAL

Cyclophosphamid

300mg/m2/d

Intervention Type: DRUG

Fludarabine

30mg/m2/d

Intervention Type: DRUG

Other Intervention Names

CBG-002 CAR-T

Eligibility Criteria

Inclusion Criteria

1. Patients with relapsed/refractory multiple myeloma aged 18-75 years;

2. BCMA expression ≥50% in bone marrow samples confirmed by Flow Cytometry or IHC is positive for BCMA expression;

3. Relapsed/refractory patients who meet the following conditions:

1. Ineffective or disease progression after receiving bortezomib (proteasome inhibitor) and lenalidomide for 3 courses;

2. Ineffective or disease progression after receiving the original treatment plan for 3 courses;

3. The interval between the last treatment and disease progression is more than 30 days;

4. There is currently no indication for hematopoietic stem cell transplantation, or the patient refuses to do hematopoietic stem cell transplantation;

5. The definition of disease progression refers to the "2014 IMWG Standards", and at least meets the following 1 items:

e.1 Serum M protein ≥ 0.5 g/dL;

e.2 Urine M protein ≥ 200 mg/24 h;

e.3 If the serum FLC ratio is abnormal, the patient's FLC level ≥ 10 mg/dL (100 mg/L);

e.4 Evaluable plasmacytoma confirmed by biopsy;

e.5 Increase in the proportion of bone marrow plasma cells ≥25% (absolute increase ≥10%);

e.6 Bone marrow plasma cells account for 30% of the total bone marrow cells;

4. Estimated survival time> 12 weeks;

5. The disease status can be assessed and meet at least one of the following:

1. Serum M-protein ≥10 g/L;

2. 24h urine M-protein ≥200mg;

3. Serum FLC≥5mg/dL;

4. Plasma cell tumors that can be assessed by testing or images;

5. The proportion of bone marrow plasma cells ≥ 30%;

6. ECOG physical status score 0-1;

7. Have enough venous access for apheresis or venous blood collection, and there are no other contraindications for blood cell separation;

8. WBC ≥ 1.5×109/L; PLT ≥ 45×109/L;

9. Serum creatinine ≤ 1.5 upper limit of normal (ULN) ;

10. ALT ≤ 2.5 ULN, AST ≤ 2.5 ULN.

All laboratory test results within the above range should have no ongoing continuous supportive treatment.

Exclusion Criteria

-

Subjects who meet any of the following criteria cannot be selected for this study:

1. Systemic treatment such as lymphatic depletion with cyclophosphamide and fludarabine within 2 weeks before enrollment or single cell collection, or cell therapy within 8 weeks before treatment;

2. HCV or HIV positive; any uncontrollable active infection, including active tuberculosis, HBV DNA level ≥1×103 copies/mL;

3. Active infections occurred within 72 hours before cleansing; as long as there is no evidence of active infection and antibiotics are not in the list of prohibited drugs, subjects who continue to use preventive antibiotics, antifungal drugs or antiviral drugs are not excluded;

4. The current systemic use of cyclosporine or steroid drugs such as dexamethasone, recent or current use of inhaled steroids is not excluded;

5. Renal insufficiency, serum creatinine>1.5 upper limit of normal (ULN);

6. Liver insufficiency, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)>2.5 times ULN and direct bilirubin>1.5 times ULN;

7. Hyponatremia, blood sodium <125 mmol/L;

8. Baseline serum potassium <3.5 mmol/L (potassium supplementation can be given before participating in the study, and serum potassium recovery above this standard is not excluded);

9. Pregnant or lactating women;

10. Other serious diseases that may restrict subjects from participating in this trial (such as central nervous system disease, severe heart insufficiency, myocardial obstruction or unstable arrhythmia or unstable angina, gastric ulcer in the past 6 months , Active autoimmune diseases, etc.).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Carbiogene Therapeutics Co. Ltd.

INDUSTRY

Sponsor Role: collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wenbin Qian

Role: PRINCIPAL_INVESTIGATOR

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Locations

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Wenbin Qian

Role: CONTACT

qianwb@zju.edu.cn

13605801032

Facility Contacts

Wenbing Qian, M.D.,PhD.

Role: primary

qianwb@zju.edu.cn

+8613605801032

References

Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, Hong R, Chang AH, Yu J, Fu S, Kong D, Li L, Wang Y, Li Z, Jiang H, Huang J, Liu Z, Su N, Wei G, Hu Y, Huang H. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023 Aug;202(3):517-524. doi: 10.1111/bjh.18873. Epub 2023 May 16.

Reference Type: DERIVED

PMID: 37192741 (View on PubMed)

Other Identifiers

IR2020001474

Identifier Type: -

Identifier Source: org_study_id